Alzheimer's disease: many failed trials, so where do we go from here?

被引：17

作者：

Reiss, Allison Bethanne ^{[1
,2
]}

Glass, Amy D. ^{[1
,2
]}

Wisniewski, Thomas ^{[3
,4
,5
]}

Wolozin, Benjamin ^{[6
,7
]}

Gomolin, Irving H. ^{[1
,2
]}

Pinkhasov, Aaron ^{[8
]}

De Leon, Joshua ^{[1
,2
]}

Stecker, Mark M. ^{[9
]}

机构：

[1] NYU Long Isl Sch Med, Med, Mineola, NY 11501 USA

[2] NYU Winthrop Hosp, Mineola, NY 11501 USA

[3] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA

[4] NYU, Sch Med, Dept Pathol, New York, NY USA

[5] NYU, Sch Med, Dept Psychiat, New York, NY USA

[6] Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA

[7] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA

[8] NYU Winthrop Hosp, Dept Psychiat, Mineola, NY USA

[9] UCSF San Francisco Fresno, Neurol, Fresno, CA USA

来源：

JOURNAL OF INVESTIGATIVE MEDICINE | 2020年 / 68卷 / 06期

关键词：

Alzheimer's disease; plaque; amyloid; MRI; cognition; biomedical research; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; AMYLOID-BETA; PHASE-3; TRIAL; DEMENTIA; TAU; DIAGNOSIS; INHIBITORS; BIOMARKERS; PET;

D O I：

10.1136/jim-2020-001297

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alzheimer's disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid beta and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.

引用

页码：1135 / 1140

页数：6

共 115 条

[1] ALJANABI NM, 2020, CUREUS, V0012, DOI DOI 10.7759/CUREUS.6885
[2] [Anonymous], 2018, ALZHEIMERS DEMENT, DOI DOI 10.1016/J.JALZ.2018.02.018
[3] [Anonymous], 2016, EMBO MOL MED
[4] APOSTOLOVA LG, 2012, ALZ DIS ASSOC DIS, V0026, P00017, DOI DOI 10.1097/WAD.0B013E3182163B62
[5] ARVANITAKIS Z, 2019, JAMA J AM MED ASSOC, V0322, P01589, DOI DOI 10.1001/JAMA.2019.4782
[6] BATTY GD, 2018, J EPIDEMIOL COMMUN H, V0072, P00513, DOI DOI 10.1136/JECH-2017-209922
[7] BAWA KK, 2020, J NEUROINFLAMM, V0017, DOI DOI 10.1186/S12974-020-01750-3
[8] BOND M, 2012, HEALTH TECHNOL ASSES, V0016, P00001, DOI DOI 10.3310/HTA16210
[9] BRAAK H, 2006, ACTA NEUROPATHOL, V0112, P00389, DOI DOI 10.1007/S00401-006-0127-Z
[10] BRASURE M, 2018, ANN INTERN MED, V0168, P00030, DOI DOI 10.7326/M17-1528

← 1 2 3 4 5 6 7 8 9 10 →